Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 744

1.

18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.

Vees H, Buchegger F, Albrecht S, Khan H, Husarik D, Zaidi H, Soloviev D, Hany TF, Miralbell R.

BJU Int. 2007 Jun;99(6):1415-20. Epub 2007 Apr 8.

2.

Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?

Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.

J Nucl Med. 2014 Sep;55(9):1424-9. doi: 10.2967/jnumed.114.138313. Epub 2014 Jun 16.

3.

(18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.

Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O.

World J Urol. 2015 Nov;33(11):1749-52. doi: 10.1007/s00345-015-1547-y. Epub 2015 Apr 1.

PMID:
25824540
4.

Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.

Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.

BJU Int. 2015 Jun;115(6):874-83. doi: 10.1111/bju.12953. Epub 2015 Jan 21.

5.

The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.

Picchio M, Briganti A, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN.

Eur Urol. 2011 Jan;59(1):51-60. doi: 10.1016/j.eururo.2010.09.004. Epub 2010 Sep 15. Review.

PMID:
20869161
6.

First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.

Buchegger F, Garibotto V, Zilli T, Allainmat L, Jorcano S, Vees H, Rager O, Steiner C, Zaidi H, Seimbille Y, Ratib O, Miralbell R.

Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):68-78. doi: 10.1007/s00259-013-2540-6. Epub 2013 Oct 9.

PMID:
24104592
7.

Positron emission tomography for prostate, bladder, and renal cancer.

Schöder H, Larson SM.

Semin Nucl Med. 2004 Oct;34(4):274-92. Review.

PMID:
15493005
8.

[PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].

García JR, Soler M, Blanch MA, Ramírez I, Riera E, Lozano P, Pérez X, Delgado E, Carrio I, Lomeña F.

Rev Esp Med Nucl. 2009 May-Jun;28(3):95-100. Spanish.

9.

Does Choline PET/CT Change the Management of Prostate Cancer Patients With Biochemical Failure?

Goldstein J, Even-Sapir E, Ben-Haim S, Saad A, Spieler B, Davidson T, Berger R, Weiss I, Appel S, Lawrence YR, Symon Z.

Am J Clin Oncol. 2017 Jun;40(3):256-259. doi: 10.1097/COC.0000000000000139.

PMID:
25319322
10.

¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients.

D'Angelillo RM, Sciuto R, Ramella S, Papalia R, Jereczek-Fossa BA, Trodella LE, Fiore M, Gallucci M, Maini CL, Trodella L.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):296-302. doi: 10.1016/j.ijrobp.2014.05.050. Epub 2014 Jul 29.

PMID:
25084612
11.

[Single center experience of (18F)-fluorocholine positron emission tomography: analysis of its impact on salvage local therapy in patients with prostate adenocarcinoma].

Moussaid Y, Bonardel G, Jacob J, Métivier D, Gontier E, Bauduceau O, Durand X, Fayolle M, Houlgatte A, Foehrenbach H, Védrine L, Chargari C.

Cancer Radiother. 2013 Jul-Aug;17(4):259-64. doi: 10.1016/j.canrad.2013.01.019. Epub 2013 May 20. French.

PMID:
23702489
13.

Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation.

Wahart A, Guy JB, Vallard A, Geissler B, Ben Mrad M, Falk AT, Prevot N, de Laroche G, Rancoule C, Chargari C, Magné N.

Br J Radiol. 2016;89(1058):20150579. doi: 10.1259/bjr.20150579. Epub 2015 Dec 9.

14.

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.

Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.

J Nucl Med. 2009 Sep;50(9):1394-400. doi: 10.2967/jnumed.108.061507. Epub 2009 Aug 18. Erratum in: J Nucl Med. 2009 Oct;50(10):1578.

15.

Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.

Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, Kawashima A.

J Nucl Med. 2014 Feb;55(2):223-32. doi: 10.2967/jnumed.113.123018. Epub 2014 Jan 16.

16.

Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.

Schilling D, Schlemmer HP, Wagner PH, Böttcher P, Merseburger AS, Aschoff P, Bares R, Pfannenberg C, Ganswindt U, Corvin S, Stenzl A.

BJU Int. 2008 Aug;102(4):446-51. doi: 10.1111/j.1464-410X.2008.07592.x. Epub 2008 Apr 11.

17.

Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer.

Souvatzoglou M, Krause BJ, Pürschel A, Thamm R, Schuster T, Buck AK, Zimmermann F, Molls M, Schwaiger M, Geinitz H.

Radiother Oncol. 2011 May;99(2):193-200. doi: 10.1016/j.radonc.2011.05.005. Epub 2011 May 26.

PMID:
21620494
18.

Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.

Couñago F, Recio M, Maldonado A, Del Cerro E, Díaz-Gavela AA, Thuissard IJ, Sanz-Rosa D, Marcos FJ, Olaciregui K, Mateo M, Cerezo L.

Cancer Imaging. 2016 Dec 7;16(1):42.

19.

Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.

Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):55-63. doi: 10.1007/s00259-010-1604-0. Epub 2010 Sep 17.

PMID:
20848281
20.

11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM, Kibel AS, Andriole GL, Picus J, Welch MJ.

J Nucl Med. 2003 Apr;44(4):549-55.

Supplemental Content

Support Center